Alpha Cognition Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alpha Cognition Inc. (Nasdaq: ACOG; CSE: ACOG) develops and commercializes treatments for neurodegenerative diseases including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury; its lead product ZUNVEYL (benzgalantamine), an oral tablet formulation approved by the U.S. FDA in July 2024 for mild-to-moderate Alzheimer's disease, targets the $2 billion U.S. long-term care market with improved tolerability over existing acetylcholinesterase inhibitors; additional pipeline programs encompass ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual and intranasal formulations for mTBI-related cognitive impairment, and preclinical candidates ALPHA-0602, ALPHA-0702, and ALPHA-0802. Founded in 2000 and headquartered in Grapevine, Texas, the company operates primarily in the United States and Canada with a commercial-stage focus on ZUNVEYL sales through a specialized long-term care team engaging nursing homes, psychiatrists, and medical directors. Recent developments include a Q1 2025 U.S. commercial launch of ZUNVEYL with expanding prescriber base and pharmacy benefit manager contracts, a successful $50 million upsized public offering and Nasdaq uplisting in November 2024 followed by a $35 million oversubscribed offering in September 2025 strengthening its cash position to approximately $70 million, key leadership hires in commercial, market access, and medical affairs in early 2025, initiation of CONVERGE and BEACON long-term care studies in late 2025 and early 2026 to assess cognitive and behavioral benefits, and business development progress with partner CMS Pharma including anticipated approval in China by end-2026.
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease
CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
Alpha Cognition Announces Appointment of VP Finance and Accounting
Alpha Cognition Announces Change of Officer
Spartan Capital Securities Serves as Selling Group Member in Alpha Cognition Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's Disease
Alpha Cognition Provides Business Update
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering